FGH10019

小分子

FGH10019

F649801-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

FGH10019 is a novel sterol regulatory element-binding protein ( SREBP ) inhibitor with IC 50 of 1 μM. In Vitro Treatment of the CHO-K1 cells with analog FGH10019 decreases the percentage of the mature form of SREBP-2 (68 kDa) at lower concentrations than treatment with fatostatin. Densitometric analysis of the gels indicates that the IC 50 of analog FGH10019 is approximately 1 μM, which is 5-10 times lower than the IC 50 of fatostatin (appr 10 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo FGH10019-treated chow is fed at a dose rate calculated to provide about 0.7 mg analog FGH10019 per day, at about 23 mg/kg body weight, to 5-wk-old male ob/ob mice weighing an average of appr 30 g. After 8 wk on the analog 24-treated chow, the mice gain 8-9 % less weight than control mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 1 μM (SREBP)

FGH10019 是一种新型固醇调节元件结合蛋白（SREBP）抑制剂，IC 50 为 1 μM。

1046045-61-7

C18H19N3O2S2

373.49 g/mol

25012898

CCCC1=NC=CC(=C1)C2=NC(=CS2)C3=CC=C(C=C3)NS(=O)(=O)C

N-[4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenyl]methanesulfonamide

1S/C18H19N3O2S2/c1-3-4-16-11-14(9-10-19-16)18-20-17(12-24-18)13-5-7-15(8-6-13)21-25(2,22)23/h5-12,21H,3-4H2,1-2H3

OWAXXHRQPWGNTG-UHFFFAOYSA-N

CCCC1=NC=CC(=C1)C2=NC(=CS2)C3=CC=C(C=C3)NS(=O)(=O)C

25012898

FGH 10019;FGH-10019;FGH10019;N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide

DMSO : ≥ 38 mg/mL (101.74 mM)

1

6

6

373.092 Da

373.092 Da

109.000 Ų

25

0

515.000

0

1

3.400